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Objectives: The aim of this study is to assess the impact of dryness caused by primary Sjӧgren’s Syndrome (pSS) 
on smell, taste and sexual function in female patients, and its influence on quality of life. 
Methods: Electronic databases including MEDLINE via Ovid, Web of Science, SCOUPUS, EMBASE and COCHRANE 
LIBRARY were searched until April 2016. Studies that assessed the function of smell, taste and sexuality in pSS 
patients, defined by the American European Consensus Group (AECG) criteria. Standardised mean differences 
(SMD) for individual studies using random-effects meta-analysis were feasible. 
Results: Five studies incorporated 378 participants were included in the quantitative synthesis. The impact of 
pSS vs healthy controls was: smell SMD -0.78 (95% CI  -1.29 to -0.27); taste SMD -1.01 (95% CI  -1.54 to -0.49); 
total sexual function SMD -0.93 (95% CI -1.22 to -0.64); physical  and mental component of the quality of life 
SMD -1.28 (95% CI -1.65 to -0.90) and SMD -0.83 (95% CI -1.27 to -0.40) respectively; anxiety and depression 
SMD 0.61 (95% CI 0.02, 1.20) and SMD 0.79 (95% CI 0.43 to 1.15) respectively.  
Conclusion: pSS has a negative impact on smell, taste, sexual function and quality of life in women. 
 
Introduction 
Primary Sjögren’s Syndrome (pSS) is a systemic autoimmune rheumatic disorder of unknown origin, affecting 
women nine times more commonly than men [1]. Inflammation of exocrine glands occurs as a result of excessive 
infiltration of autoantibodies leading to functional destruction. The burden of pSS is substantial and is 
compounded by the lack of effective treatment. Dryness of mucosal surfaces is the main characteristic feature 
of this syndrome, typically dry eyes and mouth. Yet, other mucosal surfaces can also be involved such as nasal 
and vaginal mucosa and can affect associated function and interfere with quality of life [2-4].  
Smell and taste alteration are frequently reported symptoms by pSS patients. Studies have found that smell and 
taste are impaired and correlated with each other in pSS patients, and influenced by mucosal surfaces dryness 
[5, 6]. One study showed that taste disorders in Sjӧgren’s patients are less frequently found than previously 
reported, and is linked to the reduction in salivary flow rate, in a way that impedes substances from reaching 
the taste buds [7]. Others, however, reported little association between taste deficit and mucosa dryness in 
Sjӧgren’s patients [8, 9].  
Women with pSS often suffer from vaginal dryness and dyspareunia with the possible explanation for these 





association between oral symptoms and vaginal dryness in Sjӧgren’s patients [11]. Other studies suggested that 
dryness and dyspareunia could adversely impact the sexual well-being of women with pSS [13, 14]. Sexual 
wellbeing is an important aspect of quality of life and addressing this is an essential component of delivering 
holistic patient-centred care.  In this study, we aimed to determine the impact of mucosal dryness on smell, 
taste, sexual function and quality of life in women with pSS.  
 
Methods 
A prospective protocol was registered on a systematic review database (PROSPERO: CRD42015024354) [15]. 
This review was performed using recommended methods and reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [16].  
Search strategy and Eligibility criteria 
Several electronic sources for published studies from inception to June 2015 were searched. The databases 
included Ovid-Medline, Web of Science, Scopus, Embase and Cochrane Library. MeSH and Boolean logic of the 
following search terms were used: Sjogren Syndrome, Sjogren Disease, hyposmia, anosmia, smell, smell*, 
olfact*, odour, nasal, nasal*, taste, taste*, gust, gust*, tastant, flavor, flavour, gustation, ageusia, hypogeusia, 
sex, sex*, obstet*, gyne*, gynae*, vagina, vagina*, dyspareunia. Recent issues of relevant publications and the 
reference lists of included texts and relevant review articles were searched. Experts were contacted for 
additional studies and data to clarify ambiguity. No search software has been used, EndNote was employed to 
merge retrieved citations and eliminate duplications. We placed no restriction on language or study population. 
 Studies were selected for analysis if they satisfied the following criteria: i) Studies of pSS female patients vs. 
healthy controls; ii) Smell, taste and sexual dysfunction were a primary or secondary outcome; iii) Quality of life 
and mental health well-being were a secondary outcome iiii) Studies that used the American European 
Consensus Group (AECG) criteria as a standard to categorise SS patients [17]. Studies were eliminated if pSS 
diagnosis was based on clinical experience or other diagnostic criteria. Unpublished studies of the association 
has not been found. A flow chart of the study selection was generated.  
 
Data extraction and quality assessment 
All titles and abstracts for relevant studies were screened. Reasons for exclusion were documented 





reviewers (MA) and (NP). The two authors discussed the outcome with any disagreements resolved by 
consensus. The following data was extracted: study characteristics (authors, year of publication, title, country of 
the study, study design); population characteristics (inclusion and exclusion criteria, sample size, mean age, 
disease duration, response rate and drop out); intervention (type of intervention, mean score of questionnaires 
and/or clinical tests used, purpose of testing, outcome and summary of study). We modified the validated 
Newcastle-Ottawa Scale (NOS) instrument for quality assessment of the final selected studies. This modification 
was applied by including relevant items from NOS case-control, NOS cohort and the modified NOS cross-
sectional designs as described by Herzog, Alvarez-Pasquin, Diaz, Del Barrio, Estrada and Gil [18] (Supplementary-
2). Quality assessment was independently performed by MA and NP; any discrepancies were discussed and a 
third independent reviewer (KK) was involved if it could not be resolved. A star system was applied to evaluate 
primary study quality in terms of three criteria: Participant’ selection, comparability, exposure and outcome 
assessment.  
Meta-analysis 
Standardised mean differences (SMD) and 95% confidence intervals (CIs) were calculated for continuous data. 
A random–effect model was applied to reduce statistical heterogeneity in combining data in order to get an 
overall SMD. Heterogeneity was evaluated via Chi2 and I2 at a p-value of ≤ 0.05. Overall effect was assessed using 
SMD with significance set at p<0.05. Funnel plot for the detection of publication bias and subgroup analysis to 
investigate heterogeneity will be applied when the number of trials is at least ten [19]. Where necessary authors 
were contacted by email for clarification or to obtain additional data. Statistical analysis was performed using 




Final searches were undertaken in April 2016 and a total of 2767 articles were initially identified using the search 
strategy. After reviewing titles and/ or abstracts, no article studying the effect of dryness on the three elements 
together (smell, taste and sexuality) in Sjӧgren’s patients was identified. Therefore, our search strategy was 
focused on studying the effect of pSS on each element separately and on the general quality of life and mental 





articles fulfilled the criteria and were selected for qualitative and quantitative (meta-analysis) assessment 

















The characteristics of the five included studies for the current review are presented in Table 1. Primary study 
quality was adjudged as being moderate to high generally (Table-2).  One study assessed the impact of pSS on 
smell and taste, with a total of 65 participants [6], and three studies evaluated the impact of pSS on sexuality, 
with a total of 201 participants [13, 14, 20]. Three studies [13, 14, 21] evaluated the impact of sexual dysfunction 
on mental health well-being by using the Hospital Anxiety and Depression Scale (HADS), and one study [20] 
assessed the impact of sexual dysfunction on mental health using Beck’s Depression Inventory (BDI).  Four 
studies [6, 13, 14, 21] measured the effect of pSS on Qol by using the Short Form-36 (SF-36), Short Form-12 (SF-
12) and RAND 36-item Health Survey assessment tool, with a total of 314 participants. Bongi, Del Rosso, Orlandi 
and Matucci-Cerinic [21] assessed the sexual function using a different instrument modified from Hill’s 











Study design as stated 
in the article 
Screening 
Participants 





Outcome Summary of study 
 




threshold tests & 
questionnaire 
pSS = 28 
Controls = 37 
pSS =58 







Impairment  of chemosensory 
perception & QoL in pSS patients 
compared with age and gender 
matched control 





pSS = 62 
Controls = 50 






function in pSS 
Impairment but no sig. dif. between 
pSS & controls in sexuality, mental 
health, fatigue & QoL 
3. Ugurlu et al., 2014 Turkey Cross sectional Questionnaires 
 
pSS = 32 
Controls = 32 
pSS =40.1 





function in pSS 
Sexual dysfunction is affected by 
disease itself and depression. The 
disease itself is greater. Sexual 
dysfunction and depression is higher 
in pSS patients 
4. Nimwegen et al., 2015 
 
Netherland Cross-sectional Questionnaires pSS = 46 
Controls = 43 
pSS =46.3 







pSS patients experience significantly 
more sexual dysfunction and distress 
than controls. Sexual dysfunction is 
influenced by vaginal dryness, pain 
and fatigue as well as mental health 
disorders 
5. Priori et al., 2015 Italy Cross-sectional 
Vaginal pH, pelvic 
exam, 
cervicovaginal 
swabs, Pap test 
(cases only) 
questionnaires(ca




Controls = 24 
pSS = 50.4 








function in pSS 
pSS patients have lower sexual 
functioning than healthy controls, 
high level of anxiety related with low 





          Table-2 Quality assessment of the included studies measured by Modified Newcastle Ottawa Scale (M-NOS) 
 
 


































Kamel 2009 ⋆ - - - - ⋆ ⋆⋆ ⋆ ⋆ - ⋆ ⋆ High 
Bongi 2013 ⋆ - - ⋆ ⋆ ⋆ ⋆ - - - ⋆ ⋆ Moderate 
Ugurlu 2014 ⋆ - - ⋆ - - ⋆⋆ - ⋆ - ⋆ ⋆ Moderate 
Nimwegen 2015 ⋆ - ⋆ ⋆ ⋆ - ⋆⋆ - ⋆ - ⋆ ⋆ High 
Priori 2015 ⋆ ⋆ - ⋆ - ⋆ ⋆⋆ - ⋆ ⋆ ⋆ ⋆ High 





Smell and taste function 
One study (Kamel et al., 2009), of moderate quality involving a total of 28 pSS patients and 37 healthy 
participants, compared the chemosensory function of smell and taste, and its impact on quality of life in pSS 
patients versus controls. The two senses had significantly deteriorated in pSS patients compared to age and 
gender matched controls, with about 50% of subjects suffering from hyposmia (p = 0.002) and 70% suffering 
from hypogeusia (p < 0.001). However, salivary flow rate measurement was not undertaken in a similar manner 
for all participants; therefore, the relationship between the impaired chemosensory perception and the degree 
of salivary glands dysfunction was not reported. In terms of the correlation between both senses, smell function 
was positively correlated with that of taste (r = 0.35, p = 0.004). The study also proved that age was inversely 
associated with smell thresholds (r = -0.252; p = 0.04), whilst no impact was found to be on taste dysfunction (r 
= -0.15, p = 0.236). Results of this study may not be applicable to the female population of Sjӧgren’s patients as 
the sample consisted of 11% males in the pSS group. This study was the only one that met our inclusion criteria 
in terms of the assessment of smell and taste in Sjӧgren’s patients; meta-analysis for these elements was 
therefore not possible.        
Sexual function  
Sexual function has been measured by FSFI in three included studies [13, 14, 20], and was compared between 
pSS patients (102 patients) and healthy controls (99 participants). A random-effects model was used in all 
domains, and the pooled results displayed significant difference between pSS patients and healthy controls. The 
SMD of the FSFI scores of pSS patients were lower than that of controls on each domain of sexual function: 
Desire (P < 0.00001, SMD -0.72, 95% CI -1.00 to -0.43), Arousal (P < 0.00001, SMD -0.93, 95% CI -1.22 to -0.64), 
lubrication (P < 0.00001, SMD -1.07, 95% CI -1.37 to -0.77), Orgasm (P= 0.001, SMD -0.60, 95% CI -0.96 to -0.23), 
Satisfaction (P < 0.0001, SMD -0.60, 95% CI -0.91 to -0.30), Pain (P < 0.0001, SMD -0.92, 95% CI -1.34 to -0.51), 
total FSFI (P < 0.00001, SMD -0.93, 95% CI -1.22 to -0.64).  
Quality of Life  
The quality of life of pSS patients has been assessed by SF-36, SF-12 and RAND-36 in four eligible studies [6, 13, 
14, 21] and was compared between pSS patients (160 patients) and healthy controls (154 participants). A 
random-effect model was used in the meta-analysis of the Physical (PCS) and Mental Component Summary 
(MCS) due to statistical heterogeneity between studies (P = 0.08, I2 = 55%; P = 0.02, I2 = 70% respectively). The 





healthy controls on PCS and MCS (P < 0.00001, SMD -1.28, 95% CI -1.65 to -0.90; P = 0.0002, SMD -0.83, 95% CI 
-1.27 to -0.40 respectively). 
Mental health well-being 
Mental health well-being has been measured by HADS in four included studies [13, 14, 20, 21] and was compared 
between 132 pSS patients vs. 117 healthy controls in Anxiety (HADS-A), and 164 pSS patients vs. 149 healthy 
controls in Depression (HADS-D) respectively. A random-effect model was used in the meta-analysis due to 
statistical heterogeneity among studies (P= 0.004, I2 = 82%; P = 0.07, I2 = 57% respectively).  
The pooled results of HADS-A and HADS-D showed that the SMD was significantly higher in pSS patients than in 
controls (P = 0.04, SMD 0.61, 95% CI 0.02 to1.20; P < 0.0001, SMD 0.79, 95% CI 0.43 to 1.15 respectively) (Table-
3). 
     
Publication bias and subgroup analysis  































Figure-2 Forest plots of the sexual function A - G assessed by FSFI (A) Desire, (B) Arousal, (C) Lubrication, (D) 
Orgasm, (E) Satisfaction, (F) Pain, and (G) total FSFI. Quality of life (H and I) assessed by SF-12, SF-36 and RAND-
36, (H) Physical component, (I) Mental component. Mental health well-being (J and K) assessed by HADS and 











The primary purpose of this review is to systematically assess the effect of mucosa dryness which is known to 
be part of pSS, on the senses that share this aspect, and whether a dysfunction exists, will be impacting the 
quality of life of patients.  During our search, there was no one study in the literature assessing the impact of 
pSS on the smell and taste and sexuality collectively. Therefore, splitting the study’s aim into three separate 
goals has been conducted.   
Of the studies that met our inclusion criteria, Kamel et al [6] was the only study measured the effect of pSS on 
smell and taste and quality of life in pSS patients. The rest of eligible studies [13, 14, 20, 21] assessed the impact 
of sexual dysfunction on quality of life of pSS patients. 
Our meta-analysis included five studies with a total number of 378 of participants (192 cases and 186 controls). 
The quality of included studies ranged between moderate [20, 21] and high [6, 13, 14]. We were unable to 
perform funnel plot or subgroup analysis owing to the limited number of studies available in each subgroup.  
 In terms of sexual function, three studies with a total of 201 participants (102 cases and 99 controls) were 
included [13, 14, 20]. No significant heterogeneity was identified on pain domain, whilst zero heterogeneity was 
observed on desire, arousal, lubrication, satisfaction and on the total FSFI. There was only one domain (orgasm) 
with significant heterogeneity between studies. Therefore, a random-effect model was applied. In the meta-
analysis, a certain sexual dysfunction was found in pSS patients compared with healthy controls. The three 
analysed studies [13, 14, 20] came to agreement on the correlation between sexual activity and the low quality 
of mental health, where the latter may have a bidirectional effect on the sexual life. The studies also highlighted 
the impact of vaginal dryness on sexual dysfunction in pSS patients. In fact, there appear to be a suggestion in 
the literature that there are more than one element that influence sexual function in rheumatic patients, 
including joint pain, age and sex hormones [22, 23].  Two of the analysed studies [13, 14] found that sexual 
dysfunction does not correlate with the measurement assessed by physicians using the validated EULAR 
Sjӧgren’s Syndrome Disease Activity Index (ESSDAI) [18], but is associated more with the self-reported symptoms 
of the syndrome as rated by the EULAR Sjӧgren’s Syndrome Patients’ Reported Index (ESSPRI) [19]. However, 
there are no such correlations reported in the literature regarding the smell and taste.  
In the quality of life meta-analysis, heterogeneity was observed in the four included studies and random-effect 





components among individuals with pSS than in controls, which denotes to the adverse impact of the syndrome 
on patients’ quality of life as a result of the sexual dysfunction. Yet, in this meta-analysis, quality of life has also 
been negatively impacted by the deficit of chemosensation that was assessed by Kamel et al, 2009. Therefore, 
we concluded that pSS has more than one aspect that impacts on quality of life. However, future studies are 
needed to determine which aspect is the most impacting patients’ well-being.  
Screening of the mental disorders, negative impact of pSS on mental health well-being was observed in the 
patients group compared to controls. Random-effect model was applied due to statistical heterogeneity. Three 
studies were included in the meta-analysis of anxiety where higher levels were shown in pSS group compared 
to controls. Four studies were included in the meta-analysis of depression, and was also found to be worse in 
patients compared to controls. Data were pooled at the suggested cut-off point of ≥8 [24, 25] therefore, we 
concluded that pSS has significantly increased anxiety and depression levels in pSS patients compared to 
controls.  
The strength of the current review lies in its methodology that was conducted in accordance to PRISMA 
guidelines, to ensure high quality of studies selection and data extraction. Comprehensive literature search 
including all relevant electronic databases with no restriction on language, as well as manual search through 
references and journals were approached. Two reviewers worked independently with an overall agreement rate 
of 99%. Relying on a well-established diagnostic criteria of AECG in classifying pSS patients has enriched our 
inclusion criteria [17]. These criteria are valid, reliable and present a well-defined group of pSS by discriminating 
between primary and secondary SS. We had to follow restrictive inclusion criteria to reduce heterogeneity 
among studies that used different and unreliable diagnostic criteria to classify pSS patients. 
 
Limitations of this study 
The lack of primary research made it difficult to explore the potential cause of heterogeneity. However, two 
probable predictors for heterogeneity is the different age range across studies and the sample size, that is, larger 
studies demonstrate greater accuracy than smaller studies. Additional factors: the different quality of the 
included studies and selection bias in recruiting participants can also explain the resulted heterogeneity. 
Furthermore, it was not possible to adjust for potential confounders as we do not have access to studies data at 






To the best of our knowledge, the present systematic review and meta-analysis is the first analysing the impact 
of pSS on the sexual function in Sjögren’s patients. We concluded that pSS is adversely impacting patients’ sexual 
life mood status. Future work is needed to look at whether psycho-sexual counselling can help women with pSS. 
Health professionals managing cases of pSS should consider enquiring about sexual complaints, since patients 
will not bring up the problem themselves. Research is needed concerning development of vaginal dryness 
treatment for pSS patients.  
 
Conclusion 
With this systematic review and meta-analysis we present evidence of the multidimensional impact of pSS on 
patients’ well-being. Lack of primary research has been observed and therefore, further work and core outcome 
set is required to look at the effect of the syndrome on the senses of smell and taste and hence on quality of 
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